BRAF and melanoma: It enrolled untreated melanoma patients with CNS metastases ≥ 5 mm and performance status ≤ 2, either BRAF V600 wild-type or BRAF V600 mutation-positive, who had completed adjuvant anti-PD-L1 therapy or were symptomatic and/or corticosteroid-depended.